FENC - フェネック・ファ―マシュ―ティカルズ (Fennec Pharmaceuticals Inc.) フェネック・ファ―マシュ―ティカルズ

 FENCのチャート


 FENCの企業情報

symbol FENC
会社名 Fennec Pharmaceuticals Inc (フェネック・ファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 フェネック・ファーマシューティカルス(Fennec Pharmaceuticals Inc.)( 旧名:Adherex Technologies Inc.)はガンの治療法に焦点を当てる生物薬剤会社である。同社のリード製品は、臨床開発段階にある、チオ硫酸ナトリウム(STS)とエニルウラシルを含む。STSは、子供のシスプラチン難聴或いは耳毒性の予防のための第Ⅲ相臨床試験にある化学還元剤とする水溶性チオール化合物である。エニルウラシルは、ジヒドロピリミジン・デヒドロゲナーゼ(DPD)の不可逆阻害剤であり、主に体内で5-FUの急速な分解に関与する酵素である。   フェネック・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。臨床段階で、主にがん治療用の医薬品の開発に従事する。チオ硫酸ナトリウムは抗がん剤のシスプラチン誘発性難聴の予防に使用、エニルウラシルは経口薬で転移性乳がんの治療に使用される。本社所在地はノ―スカロライナ州リサ―チ・トライアングル・パ―ク。   
本社所在地 P.O. Box 13628 68 T.W. Alexander Drive Research Triangle Park NC 27709 USA
代表者氏名 Khalid Islam ハリドイスラム
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 919-636-4530
設立年月日 36039
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 3人
url www.adherex.com
nasdaq_url https://www.nasdaq.com/symbol/fenc
adr_tso
EBITDA EBITDA(百万ドル) -9.15700
終値(lastsale) 7.89
時価総額(marketcap) 148284391.74
時価総額 時価総額(百万ドル) 147.15680
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 121.51680
当期純利益 当期純利益(百万ドル) -8.79700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Fennec Pharmaceuticals Inc revenues was not reported. Net loss increased 73% to $4.2M. Higher net loss reflects General and administrative increase of 75% to $3M (expense) Research and development increase from $558K to $1.5M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.17 to -$0.22.

 FENCのテクニカル分析


 FENCのニュース

   Fennec Pharmaceuticals (NASDAQ:FENC) Downgraded by Zacks Investment Research to Strong Sell  2020/11/20 12:46:58 Transcript Daily
Zacks Investment Research downgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a strong sell rating in a research report released on Thursday, Zacks.com reports. According to Zacks, “Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development of Sodium Thiosulfate for the prevention of ototoxicity from cisplatin in […]
   Fennec Pharmaceuticals EPS misses by $0.05 (NASDAQ:FENC)  2020/11/16 12:15:09 Seeking Alpha
Fennec Pharmaceuticals (NASDAQ:FENC): Q3 GAAP EPS of -$0.24 misses by $0.05. Cash and cash equivalents were $33.2 million as of September 30, 2020. Press R
   EFFECT - FENNEC PHARMACEUTICALS INC. (0001211583) (Filer) - Stocks News Feed  2020/11/12 05:15:19 Stocks News Feed
Accepted 2020-11-12 00:15:19 Documents Stock Market Shirts | Stock Trading Mugs | Stock Trader Decor | Investing Books 1 Effectiveness Date 2020-11-10 Registration Form S-3 Document Format Files Mailing Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC 27709 Business Address PO BOX 13628 68 TW ALEXANDER DRIVE RESEARCH TRIANGLE PARK NC… Read More »EFFECT – FENNEC PHARMACEUTICALS INC. (0001211583) (Filer)
   DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/11/02 13:00:00 NewMediaWire
Los Angeles, CA - (NewMediaWire) - November 02, 2020 - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Fennec Pharmaceuticals Inc. (“Fennec” or “the Company”) (NASDAQ: FENC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 11, 2020 and August 10, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before November 2, 2020. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com. The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.
   FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action – FENC - Stocks News Feed  2020/11/01 20:45:52 Stocks News Feed
Share this Stock Information NEW YORK, Nov. 01, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ:FENC) between February 11, 2020 and August 10, 2020, inclusive (the “Class Period”), of the important November 2, 2020 lead plaintiff deadline in the securities… Read More »FINAL DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Reminds Fennec Pharmaceuticals Inc. Investors of the Important November 2 Deadline in Securities Class Action – FENC
   ROSEN, A HIGHLY RANKED FIRM, Announces Filing of Securities Class Action Lawsuit Against Fennec Pharmaceuticals Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - FENC  2020/09/14 21:24:00 PR Newswire
NEW YORK, Sept. 14, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Fennec Pharmaceuticals Inc. (NASDAQ: FENC) between February 11, 2020 and August 10, 2020, inclusive (the…
   FENC SHAREHOLDER ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fennec Pharmaceuticals Inc.  2020/09/11 13:11:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action that has been filed on behalf of investors that purchased or acquired the securities of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) between February 11, 2020 and August 10, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the United States Distr
   FENC Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Fennec Pharmaceuticals Inc. Investors of Class Action and Encourages Investors to Contact the Firm  2020/09/09 15:00:00 PR Newswire
NEW YORK, Sept. 9, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Fennec Pharmaceuticals Inc. ("Fennec" or the "Company") (NASDAQ: FENC) and certain of its officers, on behalf of…
   INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action Lawsuit Against Fennec Pharmaceuticals Inc.  2020/09/04 23:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)---- $FENC #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of North Carolina on behalf of those who acquired Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) (NASDAQ: FENC) securities during the period from February 11, 2020 through August 10, 2020, both dates inclusive, (the “Class Period”). Investors have until November 2, 2020 to apply to the Court to be appointed as lead plaint
   SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm  2020/09/04 15:49:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $FENC #FENC--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Fennec Pharmaceuticals Inc.
   The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs  2020/06/19 11:41:54 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Alpine Immune Sciences Inc (NASDAQ: ALPN )( announced a licensing agreement with AbbVie Inc (NYSE: ABBV ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Castle Biosciences Inc (NASDAQ: CSTL ) Cytokinetics, Inc. (NASDAQ: CYTK ) DiaMedica Therapeutics Inc (NASDAQ: DMAC ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Neoleukin Therapeutics Inc (NASDAQ: NLTX ) Neubase Therapeutics Inc (NASDAQ: NBSE ) Ocular Therapeutix Inc (NASDAQ: OCUL ) Ovid Therapeutics Inc (NASDAQ: OVID ) Passage Bio Inc (NASDAQ: PASG ) Pliant Therapeutics Inc (NASDAQ: PLRX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Royalty Pharma plc (NASDAQ: RPRX ) (IPOed Monday) Sarepta Therapeutics Inc (NASDAQ: SRPT )(announced a licensing agreement with Selecta Biosciences Inc (NASDAQ: SELB ) for licensing the latter's immune tolerance platform, ImmTOR for use in Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TELA Bio Inc (NASDAQ: TELA ) TFF Pharmaceuticals Inc (NASDAQ: TFFP ) Trevena Inc (NASDAQ: TRVN ) Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows June 18) CALLIDITAS THER/S ADR (NASDAQ: CALT ) Stocks In Focus Mylan Wins Patent Lawsuit Against Biogen With Respect To Multiple Sclerosis Drug Mylan NV (NASDAQ: MYL ) said the U.S.
   Hedge Funds Souring On Fennec Pharmaceuticals Inc. (FENC)  2020/06/15 01:50:14 Yahoo Finance
In this article you are going to find out whether hedge funds think Fennec Pharmaceuticals Inc. (NASDAQ:FENC) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge
   Fennec Pharmaceuticals (NASDAQ:FENC) Upgraded to Buy at Zacks Investment Research  2019/11/16 20:37:18 Modern Readers
Zacks Investment Research upgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) from a hold rating to a buy rating in a research report report published on Friday morning, Zacks.com reports. The brokerage currently has $5.75 target price on the stock. According to Zacks, “Fennec Pharmaceuticals Inc. is a clinical-stage biotechnology company. It is focused on the development […]
   FY2019 Earnings Forecast for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Issued By Wedbush  2019/11/15 18:30:47 Modern Readers
Fennec Pharmaceuticals Inc (NASDAQ:FENC) – Equities researchers at Wedbush upped their FY2019 earnings per share estimates for shares of Fennec Pharmaceuticals in a research report issued to clients and investors on Wednesday, November 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($0.56) for the year, up from […]
   The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes  2019/06/13 11:44:09 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp (NASDAQ: TECH ) EXACT Sciences Corporation (NASDAQ: EXAS ) Insulet Corporation (NASDAQ: PODD ) Kodiak Sciences Inc (NASDAQ: KOD ) ZIOPHARM Oncology Inc. (NASDAQ: ZIOP ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 12) Acorda Therapeutics Inc (NASDAQ: ACOR ) Amneal Pharmaceuticals Inc (NYSE: AMRX ) ANCHIANO THERAP/S ADR (NASDAQ: ANCN ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Aridis Pharmaceuticals Inc (NASDAQ: ARDS ) BRAINSWAY LTD/S ADR (NASDAQ: BWAY ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Innovate Biopharmaceuticals Inc (NASDAQ: INNT ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Minerva Neurosciences Inc (NASDAQ: NERV ) Navidea Biopharmaceuticals Inc (NYSE: NAVB ) NextCure Inc (NASDAQ: NXTC ) Novavax, Inc. (NASDAQ: NVAX ) Novus Therapeutics Inc (NASDAQ: NVUS ) Obseva SA (NASDAQ: OBSV ) RA Medical Systems Inc (NYSE: RMED ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Sensus Healthcare Inc (NASDAQ: SRTS ) Sierra Oncology Inc (NASDAQ: SRRA ) Unum Therapeutics Inc (NASDAQ: UMRX ) Zomedica Pharmaceuticals Corp (NYSE: ZOM ) Stock In Focus Savara's Pulmonary Disease Drug Does Not Meet Primary Endpoint In Late-stage Study Savara Inc (NASDAQ: SVRA ) said a Phase 3 study dubbed IMPALA that evaluated its …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 フェネック・ファ―マシュ―ティカルズ FENC Fennec Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)